RESCEU: Burden of disease of RSV in older adults, version 1.0
Research type
Research Study
Full title
REspiratory Syncytial virus Consortium in EUrope (RESCEU) study: Defining the burden of disease of Respiratory Syncytial Virus in older adults.
IRAS ID
224156
Contact name
Christopher Butler
Contact email
Sponsor organisation
University of Oxford
Duration of Study in the UK
1 years, 10 months, 30 days
Research summary
The Respiratory Syncytial Virus (RSV) causes severe disease in individuals at the extremes of the age spectrum and in high risk groups. There is a substantial gap in knowledge on morbidity and associated healthcare and social costs in Europe. These long term aftereffects pose a substantial additional burden on the healthcare system. RSV is also a significant cause of Acute Respiratory Tract Infection (ARTI) morbidity in elderly and COPD patients. Treatment options are limited and generally only supportive care is provided to those with severe RSV ARTI. Various new RSV vaccines and therapeutics could be available in the near future. To use these in the best possible way and to guide their development and implementation, it is necessary to determine the burden of RSV disease in Europe to gain a better insight in disease severity in young children and older adults and the associated societal and healthcare costs. RESCEU is an Innovative Medicine Initiative (IMI) funded by the EU under the H2020 framework which has been set up to perform the first prospective multicentre study in both older adults and children to provide accurate data on RSV disease incidence and long term airway morbidity and economic consequences of RSV infection. The older adults (≥60 years) will be recruited from general practitioner (GP) practices between May and October of each year for 2 consecutive years based on pre-specified selection criteria. The blood samples, nasopharyngeal (a longer version of a cotton bud for collecting nasal mucus)and oropharyngeal (throat) swabs will be collected throughout the season and will be analysed to observe the prevalence and burden of RSV in this population and to understand the effect on quality of life.
REC name
London - Central Research Ethics Committee
REC reference
17/LO/1210
Date of REC Opinion
18 Jul 2017
REC opinion
Further Information Favourable Opinion